Please Wait
Applying Filters...
menu
    • menu

    Technical details about Vonoprazan fumarate (JAN), learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    CHSD Vonoprazan Fumarate

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Vonoprazan fumarate (JAN)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,787Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Tak-438, 1260141-27-2, 881681-01-2, Vonoprazan fumurate, 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine fumarate, Tak 438
    Molecular Formula
    C21H20FN3O6S
    Molecular Weight
    461.5  g/mol
    InChI Key
    ROGSHYHKHPCCJW-WLHGVMLRSA-N
    FDA UNII
    4QW3X4AMLB
    Vonoprazan Fumarate is the fumarate salt form of vonoprazan, a pyrrole derivative and reversible potassium-competitive acid blocker (P-CAB), with potential antacid activity. Upon administration, vonoprazan specifically and competitively binds to the gastric hydrogen-potassium ATPase (H+/K+ ATPase) proton pump at or, more likely, near its potassium ion (K+) binding site and sterically inhibits K+ binding. This blocks the activation of the H+/K+ ATPase by K+, inhibits the proton pump and prevents gastric acid secretion, thereby lowering gastric acid levels.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (E)-but-2-enedioic acid;1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine
    2.1.2 InChI
    InChI=1S/C17H16FN3O2S.C4H4O4/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14;5-3(6)1-2-4(7)8/h2-9,11-12,19H,10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
    2.1.3 InChI Key
    ROGSHYHKHPCCJW-WLHGVMLRSA-N
    2.1.4 Canonical SMILES
    CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3.C(=CC(=O)O)C(=O)O
    2.1.5 Isomeric SMILES
    CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3.C(=C/C(=O)O)\C(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    4QW3X4AMLB
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine

    2. Tak 438

    3. Tak-438

    4. Tak438

    5. Vonoprazan

    2.3.2 Depositor-Supplied Synonyms

    1. Tak-438

    2. 1260141-27-2

    3. 881681-01-2

    4. Vonoprazan Fumurate

    5. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine Fumarate

    6. Tak 438

    7. Tak-438 Monofumarate

    8. Vonoprazan Monofumarate

    9. Vonoprazan Fumarate (tak-438)

    10. 4qw3x4amlb

    11. Tak438

    12. Unii-4qw3x4amlb

    13. Takecab

    14. Vocinti

    15. (e)-but-2-enedioic Acid;1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-n-methylmethanamine

    16. 1h-pyrrole-3-methanamine, 5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-, (2e)-2-butenedioate (1:1)

    17. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine Xfumarate

    18. 1h-pyrrole-3-methanamine, 5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-, 2-butenedioate (1:1)

    19. Mfcd18633280

    20. Vonoprazan Monofumurate

    21. 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl]-n-methylmethanamine Fumarate

    22. Takecab (tn)

    23. Vonoprazan Fumarate [usan]

    24. Schembl194394

    25. Schembl194396

    26. Chembl2064032

    27. Vonoprazan Fumarate [mi]

    28. Vonoprazan Fumarate (jan/usan)

    29. Ex-a097

    30. Vonoprazan Fumarate [jan]

    31. Bcp05635

    32. Bcp13238

    33. Ex-a4001

    34. S8016

    35. Vonoprazan Fumarate [who-dd]

    36. Akos027251052

    37. Ccg-269350

    38. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine Monofumarate

    39. 5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-1h-pyrrole-3-methanamine (2e)-2-butenedioate

    40. Ac-29287

    41. Ac-29309

    42. Ds-12234

    43. Ls-14849

    44. Cs-0164592

    45. Sw220126-1

    46. D10466

    47. A854789

    48. A900258

    49. J-524312

    50. Q25104163

    51. Tak438 Fumarate;tak-438 Fumarate;tak 438 Fumarate;1260141-27-2

    52. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine Fumarate? (vonoprazan Impurity Pound(c)

    53. 2098974-13-9

    54. 5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-1h-pyrrole-3-methanamine 2-butenedioate

    2.4 Create Date
    2010-05-17
    3 Chemical and Physical Properties
    Molecular Weight 461.5 g/mol
    Molecular Formula C21H20FN3O6S
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count9
    Rotatable Bond Count7
    Exact Mass461.10568470 g/mol
    Monoisotopic Mass461.10568470 g/mol
    Topological Polar Surface Area147 Ų
    Heavy Atom Count32
    Formal Charge0
    Complexity629
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count1
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2